And don't forget ...They had put a shelf prospectus in place that has since expired - early 2023
They were planning for something big that fizzled.
I would again watch ATE's move to P2/P2 readout and GUD's move to a renewed shelf prospectus - to see if they coincide. That's a late 2023 to early 2024 thing. Not to make more geographic acquisitions (necessarily) but to set-up for partnerships in the zones they own.
Then again - if a drug or drug family comes available - the shelf prospectus could be used there (but not at this price).
And we wait !
: )